Valuation: Gyre Therapeutics, Inc.

Market Cap 644M 578M 534M 484M 904M 61.21B 916M 6.4B 2.54B 32.07B 2.42B 2.36B 102B P/E 2026 *
-15.2x
P/E 2027 * -25.8x
Enterprise Value 644M 578M 534M 484M 904M 61.21B 916M 6.4B 2.54B 32.07B 2.42B 2.36B 102B EV / Sales 2026 *
5.88x
EV / Sales 2027 * 4.61x
Free-Float
25.6%
Yield 2026 *
-
Yield 2027 * -
1 day+7.58%
1 week+7.22%
Current month-10.91%
1 month-11.16%
3 months+9.93%
6 months-12.23%
Current year-7.51%
1 week 5.7
Extreme 5.7
6.55
1 month 5.7
Extreme 5.7
7.74
Current year 5.44
Extreme 5.44
9.14
1 year 5.44
Extreme 5.44
9.14
3 years 5.44
Extreme 5.44
30.4
5 years 5.44
Extreme 5.44
30.4
10 years 5.44
Extreme 5.44
30.4
Date Insider Type Main position Quantity % Market Cap. Importance
03/08/26 Free

Director

40,000 0.0359%
03/08/26 Free

Director

40,000 0.0359%
10/06/26 Free

Director

40,000 0.0412%
Change 5-day change 1-year change 3-year change Capi.($)
+7.58%+7.22%-20.07% - 644M
-3.10%-3.43%+36.29%+67.69% 65.28B
+0.33%+7.26%+11.51%+77.95% 54.57B
+0.16%+3.69%+8.39%+101.27% 53.59B
-0.75%+2.13%+23.14%+47.25% 45.03B
-1.30%-1.11%+17.77%+120.71% 42.17B
+1.26%+2.23%+241.81%+835.31% 39.42B
-0.74%-4.84%+14.53%+44.45% 32.71B
-2.70%-7.34%+23.17%+0.36% 24.01B
+1.11%+17.90%+56.87%+47.78% 26.5B
Average +0.19%+1.75%+41.34%+149.20% 38.39B
Weighted average by Cap. -0.70%+1.72%+45.05%+148.64%

Financials

2026 *2027 *
Net sales 110M 98.39M 90.77M 82.3M 154M 10.41B 156M 1.09B 433M 5.46B 411M 402M 17.3B 140M 125M 116M 105M 196M 13.28B 199M 1.39B 552M 6.96B 524M 513M 22.05B
Net income -38.85M -34.91M -32.2M -29.2M -54.58M -3.69B -55.29M -386M -154M -1.94B -146M -143M -6.14B -32.3M -29.02M -26.77M -24.28M -45.38M -3.07B -45.96M -321M -128M -1.61B -121M -119M -5.1B
Net Debt - -
Projected Income Statement - Annual - Gyre Therapeutics, Inc.
Logo Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product and discovery and development of targeted protein degrader and degrader antibody conjugate therapies.
Employees
625
Date Price Change Volume
27/10/26 $6.530 +7.58% 126,372
26/10/26 $6.070 +3.76% 93,374
23/10/26 $5.850 -0.17% 151,483
22/10/26 $5.860 -0.68% 66,577
21/10/26 $5.900 -4.38% 131,361
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Gyre Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.070USD
Average target price
18.67USD
Spread / Average Target
+207.52%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Gyre Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. GYRE Stock